Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Kidney and Urinary TractDRG 655-major-bladder-procedures-without-cc-mcc
    Ask Trek AI about this page

    Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

    DRG 655 includes major bladder procedures performed during an inpatient stay when no Complication or Comorbidity or Major Complication or Comorbidity is coded; it covers extensive surgical management of bladder disease. This grouping matters for inpatient reimbursement because it establishes the payment weight for high-resource urologic operations under Medicare's prospective payment system.

    Customize your policy alerts

    Sign up for drg 655 policy alerts

    Get alerted when payer policies referencing 655 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 655 Overview

    DRG 655 covers hospital admissions for major bladder procedures without Complication or Comorbidity or Major Complication or Comorbidity. Cases include significant surgical interventions on the bladder such as cystectomy or complex reconstructive procedures when no additional coded complications are present. This Diagnosis-Related Group is important for Medicare payment because it groups resource use for substantial urologic operations into a single inpatient reimbursement category. Accurate coding and documentation determine assignment to this DRG and thus the applicable Medicare inpatient payment.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Prospective randomized trials comparing perioperative surgical techniques and approaches for major bladder procedures (for example open versus minimally invasive/robotic cystectomy or different urinary diversion methods). These studies enroll patients undergoing major bladder surgery, often for muscle-invasive bladder cancer or benign indications requiring cystectomy, and evaluate intraoperative variables, complication rates, operative time, and short-term morbidity. Results inform surgeons and hospital administrators about procedure-related resource use, expected LOS, and complication profiles that drive DRG-based costs and reimbursement planning.
    • Comparative effectiveness studies assessing enhanced recovery after surgery (ERAS) protocols and bundled perioperative care pathways in patients receiving major bladder procedures. These observational or pragmatic trials examine multimodal analgesia, fluid management, early feeding and mobilization, and standardized discharge criteria across heterogeneous inpatient populations, measuring readmissions, post-discharge complications, and total cost of care. Payers and provider networks use this evidence to design care bundles and payment models that reduce variability, lower preventable complications, and optimize reimbursement under the DRG.
    • Longer-term outcomes and quality-of-life cohort studies following patients after major bladder procedures, focusing on functional outcomes (continence, sexual function), stoma or diversion-related complications, and health resource utilization up to 1–5 years post-discharge. These studies target survivors of major bladder surgery, including older adults with multiple comorbidities, tracking rehospitalizations, outpatient visits, and durable impacts on independence and long-term care needs. Findings are critical for payers and case managers to project long-term costs, post-acute care needs, and to align discharge planning and coverage policies with expected downstream utilization.

    Related Codes

    650-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITH-MCC

    Kidney Transplant with Hemodialysis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    651-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITHOUT-MCC

    Kidney Transplant with Hemodialysis without MCC: Inpatient Reimbursement Overview

    652-KIDNEY-TRANSPLANT

    Kidney Transplant: Inpatient Reimbursement Overview

    653-MAJOR-BLADDER-PROCEDURES-WITH-MCC

    Major Bladder Procedures with MCC: Inpatient Reimbursement Overview

    654-MAJOR-BLADDER-PROCEDURES-WITH-CC

    Major Bladder Procedures with CC: Inpatient Reimbursement Overview

    656-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

    657-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Neoplasm with CC: Inpatient Reimbursement Overview

    658-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITHOUT-CC-MCC

    Kidney and Ureter Procedures for Neoplasm without CC/MCC: Inpatient Reimbursement Overview

    659-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Non-Neoplasm with MCC: Inpatient Reimbursement Overview

    660-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Non-Neoplasm with CC: Inpatient Reimbursement Overview

    Showing 1–10 of 41

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.